8.7 C
Glasgow
Tuesday, November 11, 2025
spot_img

More News

Amgen reveals cardiovascular drug results

Jim Cornall -
Amgen has announced results from the phase 3 VESALIUS-CV clinical trial, which showed that Repatha (evolocumab) achieved statistically significant...

Pila Pharma’s capital raise oversubscribed by 293% to fund obesity studies

Jim Cornall -
Biotech company Pila Pharma has completed an oversubscribed share issue on Nasdaq First North in Stockholm. The raised capital will...

Base to Base biotech podcast 34: World Immunization Day and infertility

Jim Cornall -
It’s World Immunization Day on Monday, so we had a chat with Geovax chairman, president and CEO David Dodd,...

Lilly investing $1.2bn in Puerto Rico facility

Jim Cornall -
Eli Lilly and Company has announced a planned investment of more than $1.2bn to expand and modernise its Lilly...

Launch of major diabetes fundraiser

Jim Cornall -
The T1D Fund: A Breakthrough T1D Venture, LLC, an impact investment fund focused on accelerating life-changing solutions to treat,...

The future of in vivo cell engineering?

Jim Cornall -
CREATE Medicines, Inc. has presented new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, at the...

AI-designed alopecia drug completes US phase I trial

Jim Cornall -
AnHorn Medicines has announced positive results from its US phase I clinical trial of AH-001, an AI-generated topical protein...

Valthos raises $30m to build next-generation biodefence

Jim Cornall -
Valthos has raised $30m in seed financing to support the development of next-generation biodefense systems. The funding came from OpenAI...

CAR-T therapy in Korea

Jim Cornall -
Nanjing IASO Biotechnology signed an agreement with Korea's GC Cell to introduce the CAR-T therapy Fucaso (Equecabtagene Autoleucel) to...

Myrio Therapeutics to work with research institutions on solid tumour T-cell immunotherapeutics

admin -
Myrio Therapeutics has announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU...

Positive topline results for frontotemporal degeneration treatment

Jim Cornall -
Vesper Bio ApS has announced positive topline results from its phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic...

Lilly and NVIDIA building industry’s most powerful AI supercomputer

Jim Cornall -
Eli Lilly and Company is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration...

New findings pave the way for ear infection vaccine

Jim Cornall -
New findings may lead to the development of a vaccine to protect against a very common type of ear...

Immune checkpoint inhibitors promote tissue repair

Jim Cornall -
Immune checkpoint inhibitors are known as a form of cancer treatment. Researchers at UZH in Switzerland have now identified...

Base to Base biotech podcast 33: Pain relief, fungi and psychedelics

Jim Cornall -
This week, we have conversations with Cosmo Feilding Mellen, CEO of Beckley Psytech; Sirli Rosenvald, CEO of Estonian company...

Montreal biotech LifeLore Pathways launches to accelerate microbial innovation

Jim Cornall -
Proventus Bioscience has launched LifeLore Pathways, a new independent biotech company based in Montreal. While Proventus specialises in mature, large-scale...

Positive phase III results for idiopathic nephrotic syndrome drug

Jim Cornall -
Genentech has announced statistically significant and clinically meaningful results from the phase III INShore study of Gazyva (obinutuzumab) in...

A new era in Alzheimer’s therapy?

Jim Cornall -
H₂ Global Group’s subsidiary, H₂ Medical Technologies, has received official approval from The State Institute for Drug Control (SÚKL)...

China’s first AI drug completes phase III trial

Jim Cornall -
METiS TechBio says its internally developed small-molecule candidate MTS-004 has successfully met the primary endpoint in its phase III...

Hopes for anti-ulcer vaccine

Jim Cornall -
It was thought that painful stomach ulcers were caused by eating spicy foods or having an unhealthy diet. However,...

Lilly to acquire Adverum Biotechnologies

Jim Cornall -
Eli Lilly and Company and Adverum Biotechnologies, Inc., a clinical-stage company pioneering the use of intravitreal gene therapy with...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media